| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.19 | 0.0001 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.14 | 0.006 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.15 | 0.01 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.1 | 0.02 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | Panobinostat | CCLE | pan-cancer | AAC | 0.089 | 0.04 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.09 | 0.06 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.092 | 0.08 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | 0.086 | 0.08 |